Soluble urokinase plasminogen activator receptor in venous ulcers

Compression therapy remains the only treatment option for venous ulcers with <100% success. A better understanding of the mechanisms regulating venous ulcer healing might give rise to better treatments. Urokinsae plasminogen activator receptor (uPAR), a GPI anchored 3‐domain protein exists either...

Full description

Bibliographic Details
Main Author: Ahmad, Anwar
Published: King's College London (University of London) 2014
Subjects:
Online Access:http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.628456
id ndltd-bl.uk-oai-ethos.bl.uk-628456
record_format oai_dc
spelling ndltd-bl.uk-oai-ethos.bl.uk-6284562016-06-21T03:30:27ZSoluble urokinase plasminogen activator receptor in venous ulcersAhmad, Anwar2014Compression therapy remains the only treatment option for venous ulcers with <100% success. A better understanding of the mechanisms regulating venous ulcer healing might give rise to better treatments. Urokinsae plasminogen activator receptor (uPAR), a GPI anchored 3‐domain protein exists either attached to cell wall or in soluble forms (suPARI‐III, suPARI & suPARII‐III fragments). Cleavage of uPAR results in a number of nonproteolytic functions that may be important in wound healing. Our aim was to determine whether suPAR and its fragments are present in the environment of venous ulcers and whether this receptor has a role in ulcer‐healing. Ulcer exudates and ulcer tissue biopsies were obtained from patients with confirmed venous leg ulcers. Venous ulcers that healed within 6months of compression therapy were classified as healers (H) while those that did not heal in this time were defined as non‐healers (NH). Time resolved fluorescence immunoassays (TR‐FIA) were validated for measurement of suPAR fragments. TR‐FIAs specifically detected their antigens in wound exudates, but not in tissue homogenates. All forms of suPAR fragments were detected within venous ulcer exudates. Levels of all 3 suPAR fragments were significantly higher in exudates obtained from H compared to NH. ELISA analysis of uPA and plasminogen acitvator inhibitor (PAI‐1) antigen revealed that levels were similar in ulcer exudates and tissue homogenates from H and NH. 9 Treatment of scratched keratinocyte cultures with exudates from H resulted in a greater coverage of the scratch compared with NH. Depletion of suPAR from exudates obtained from H resulted in cell death. Results from this study have shown the presence of suPAR fragments within venous ulcers with higher presence of suPAR fragments in H compared to NH. This data suggests a role of suPAR and its fragments in ulcer healing, although the precise mechanisms involved remain to be identified. Measurement of suPAR fragments may provide a prognostic indicator and a therapeutic target for the treatment of venous ulcers.616.5King's College London (University of London)http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.628456https://kclpure.kcl.ac.uk/portal/en/theses/soluble-urokinase-plasminogen-activator-receptor-in-venous-ulcers(74f5dffc-db59-478e-bf87-46b476092e31).htmlElectronic Thesis or Dissertation
collection NDLTD
sources NDLTD
topic 616.5
spellingShingle 616.5
Ahmad, Anwar
Soluble urokinase plasminogen activator receptor in venous ulcers
description Compression therapy remains the only treatment option for venous ulcers with <100% success. A better understanding of the mechanisms regulating venous ulcer healing might give rise to better treatments. Urokinsae plasminogen activator receptor (uPAR), a GPI anchored 3‐domain protein exists either attached to cell wall or in soluble forms (suPARI‐III, suPARI & suPARII‐III fragments). Cleavage of uPAR results in a number of nonproteolytic functions that may be important in wound healing. Our aim was to determine whether suPAR and its fragments are present in the environment of venous ulcers and whether this receptor has a role in ulcer‐healing. Ulcer exudates and ulcer tissue biopsies were obtained from patients with confirmed venous leg ulcers. Venous ulcers that healed within 6months of compression therapy were classified as healers (H) while those that did not heal in this time were defined as non‐healers (NH). Time resolved fluorescence immunoassays (TR‐FIA) were validated for measurement of suPAR fragments. TR‐FIAs specifically detected their antigens in wound exudates, but not in tissue homogenates. All forms of suPAR fragments were detected within venous ulcer exudates. Levels of all 3 suPAR fragments were significantly higher in exudates obtained from H compared to NH. ELISA analysis of uPA and plasminogen acitvator inhibitor (PAI‐1) antigen revealed that levels were similar in ulcer exudates and tissue homogenates from H and NH. 9 Treatment of scratched keratinocyte cultures with exudates from H resulted in a greater coverage of the scratch compared with NH. Depletion of suPAR from exudates obtained from H resulted in cell death. Results from this study have shown the presence of suPAR fragments within venous ulcers with higher presence of suPAR fragments in H compared to NH. This data suggests a role of suPAR and its fragments in ulcer healing, although the precise mechanisms involved remain to be identified. Measurement of suPAR fragments may provide a prognostic indicator and a therapeutic target for the treatment of venous ulcers.
author Ahmad, Anwar
author_facet Ahmad, Anwar
author_sort Ahmad, Anwar
title Soluble urokinase plasminogen activator receptor in venous ulcers
title_short Soluble urokinase plasminogen activator receptor in venous ulcers
title_full Soluble urokinase plasminogen activator receptor in venous ulcers
title_fullStr Soluble urokinase plasminogen activator receptor in venous ulcers
title_full_unstemmed Soluble urokinase plasminogen activator receptor in venous ulcers
title_sort soluble urokinase plasminogen activator receptor in venous ulcers
publisher King's College London (University of London)
publishDate 2014
url http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.628456
work_keys_str_mv AT ahmadanwar solubleurokinaseplasminogenactivatorreceptorinvenousulcers
_version_ 1718313297643569152